Research progress on the correlation between dermatological immune-related adverse events and clinical outcome of PD-1/PD-L1 inhibitors

VernacularTitle:皮肤免疫相关不良事件与PD-1/PD-L1抑制剂临床疗效相关性的研究进展
Author: Xinjing DING ¹ ; Jianghua DING
Author Information

1. 南昌大学第一临床医学院，南昌　330006
Keywords: Treatment outcome; Dermatological immune-related adverse events; PD-1/PD-L1 inhibitors
From: Journal of International Oncology 2022;49(4):225-228
CountryChina
Language:Chinese
Abstract: Immunotherapy represented by PD-1/PD-L1 inhibitors has become the main treatment of malignant tumors. However, the adverse events caused by immunotherapy can not be ignored. Among them, dermatological immune-related adverse events (irAEs) occur with the highest incidence. Most dermatological irAEs belong to grade Ⅰ-Ⅱ, which does not affect the application of PD-1/PD-L1 inhibitors. The pathogenesis of dermatological irAEs is not fully understood. The most common types of dermatological irAEs are rash, pruritus and vitiligo. The domestic PD-1 inhibitor camrelizumab has unique adverse reactions of reactive cutaneous capillary endothelia proliferation (RCCEP) . It is found that dermatological irAEs can predict the clinical efficacy of PD-1/PD-L1 inhibitors in patients with malignant melanoma and non-small cell lung cancer (NSCLC) , especially RCCEP can be used as a potential biomarker of the efficacy of camrelizumab in the treatment of NSCLC, hepatocarcinoma, and esophageal cancer.